Colchicine - CAS 64-86-8

Colchicine - CAS 64-86-8 Catalog number: BADC-00004

* Please be kindly noted products are not for therapeutic use. We do not sell to patients.

Colchicine, a toxic plant-derived alkaloid extracted from plants of the genus Colchicum, inhibits microtubule polymerization (IC50 = 3.2 μM). It inhibits the growth of MCF-7 human breast carcinoma cells and has anti-inflammatory activity. Colchicine can lower body temperature, inhibit the respiratory center, enhance the effect of sympathomimetic drugs, constrict blood vessels, and raise blood pressure.

Category
ADCs Cytotoxin
Product Name
Colchicine
CAS
64-86-8
Catalog Number
BADC-00004
Molecular Formula
C22H25NO6
Molecular Weight
399.44
Colchicine

Ordering Information

Catalog Number Size Price Quantity
BADC-00004 1 g $298
Inquiry
Description
Colchicine, a toxic plant-derived alkaloid extracted from plants of the genus Colchicum, inhibits microtubule polymerization (IC50 = 3.2 μM). It inhibits the growth of MCF-7 human breast carcinoma cells and has anti-inflammatory activity. Colchicine can lower body temperature, inhibit the respiratory center, enhance the effect of sympathomimetic drugs, constrict blood vessels, and raise blood pressure.
Synonyms
(S)-N-(5,6,7,9-Tetrahydro-1,2,3,10-tetramethoxy-9-oxobenzo[a]heptalen-7-yl)acetamide; (-)-Colchicine; Colchineos; Colchisol; Colcin; Colsaloid; Condylon; NSC 757
IUPAC Name
N-[(7S)-1,2,3,10-tetramethoxy-9-oxo-6,7-dihydro-5H-benzo[a]heptalen-7-yl]acetamide
Canonical SMILES
CC(=O)NC1CCC2=CC(=C(C(=C2C3=CC=C(C(=O)C=C13)OC)OC)OC)OC
InChI
InChI=1S/C22H25NO6/c1-12(24)23-16-8-6-13-10-19(27-3)21(28-4)22(29-5)20(13)14-7-9-18(26-2)17(25)11-15(14)16/h7,9-11,16H,6,8H2,1-5H3,(H,23,24)/t16-/m0/s1
InChIKey
IAKHMKGGTNLKSZ-INIZCTEOSA-N
Density
1.32 g/cm3
Solubility
Slightly soluble in Chloroform, Methanol
Melting Point
150-160°C (dec.)
LogP
1.3
Clinical Trial Information
NCT NumberTitleCondition Or DiseasePhaseStart DateSponsorStatus
NCT00000577Asthma Clinical Research Network (ACRN)AsthmaPhase 3September 1993Milton S. Hershey Medical CenterWithdrawn
NCT00004368Phase I Study of Colchicine Therapy in Childhood Hepatic CirrhosisCirrhosisPhase 1May 1990National Center for Research Resources (NCRR)Unknown status
NCT00004748Low-Dose Oral Methotrexate Versus Colchicine for Primary Biliary CirrhosisLiver Cirrhosis, BiliaryPhase 3November 1989National Center for Research Resources (NCRR)Completed
NCT00128414Study of Colchicine to Treat and Prevent Recurrent Pericarditis (First Episode)PericarditisPhase 3August 2005Azienda Sanitaria Locale 3, TorinoCompleted
NCT00128427Study of Colchicine to Prevent the Postpericardiotomy SyndromePostpericardiotomy SyndromePhase 3June 2005Azienda Sanitaria Locale 3, TorinoCompleted
Appearance
White to Yellow Solid
Purity
>98%
Quantity
Grams-Kilos
Quality Standard
CP2010
Storage
Tightly closed. Dry. Keep in a well-ventilated place. Light sensitive.
Boiling Point
726.0±60.0°C at 760 mmHg
Form
Powder
1.Colchicine Therapy in Acute Coronary Syndrome Patients acts on Caspase-1 to Suppress NLRP3 Inflammasome Monocyte Activation.
Robertson S1, Martinez GJ2, Payet CA3, Barraclough JY4, Celermajer DS4, Bursill C3, Patel S4. Clin Sci (Lond). 2016 Apr 21. pii: CS20160090. [Epub ahead of print]
Rationale<: Inflammasome activation, with subsequent release of pro-inflammatory cytokines IL-1β and IL-18, has recently been implicated in atherosclerosis-associated inflammation.
2.Colchicine aggravates coxsackievirus B3 infection in mice.
Smilde BJ1, Woudstra L2, Fong Hing G1, Wouters D3, Zeerleder S4, Murk JL5, van Ham M3, Heymans S6, Juffermans LJ7, van Rossum AC7, Niessen HW8, Krijnen PA2, Emmens RW9. Int J Cardiol. 2016 Apr 19;216:58-65. doi: 10.1016/j.ijcard.2016.04.144. [Epub ahead of print]
BACKGROUND: There is a clinical need for immunosuppressive therapy that can treat myocarditis patients in the presence of an active viral infection. In this study we therefore investigated the effects of colchicine, an immunosuppressive drug which has been used successfully as treatment for pericarditis patients, in a mouse model of coxsackievirus B3(CVB3)-induced myocarditis.
3.Pyridine Based Antitumour Compounds Acting at the Colchicine Site.
Álvarez R, Aramburu L, Puebla P, Caballero E, González M, Vicente A, Medarde M, Peláez R1. Curr Med Chem. 2016;23(11):1100-30.
Antimitotics binding at the colchicine site of tubulin are important antitumour and vascular disrupting agents. Pyridines and azines are privileged scaffolds in medicinal chemistry and in recent years many colchicine site ligands (CSL) have incorporated them into their structures with the aim of improving their pharmacokinetic and pharmacodynamics properties. CSL have been classified according to their chemical structures and the chemical structures of the pyridine and azine containing antimitotic compounds are described. The designed principles behind the structural modifications and the achieved effect on the biological activity upon inclusion of these heterocycles are also discussed. Lessons from the achievements and failures have been extracted and future perspectives delineated.
The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Historical Records: Idarubicin | Colchicine
Why Choose BOC Sciences?

Customer Support

Providing excellent 24/7 customer service and support

Project Management

Offering 100% high-quality services at all stages

Quality Assurance

Ensuring the quality and reliability of products or services

Global Delivery

Ensuring timely delivery of products worldwide

Questions & Comments
Verification code
Send Inquiry
Verification code
Inquiry Basket